RAD001 in Relapsed or Refractory AML, ALL, CML in Blastic-Phase, Agnogenic Myeloid Metaplasia, CLL, T-Cell Leukemia, or Mantle Cell Lymphoma
Phase 1/2 Completed
29 enrolled
CRAD001NUS175T
Phase 1 Completed
22 enrolled
ENCERT
Phase 1 Completed
8 enrolled
Maintenance Rituximab With mTor Inhibition After High-dose Consolidative Therapy in Lymphoma
Phase 2 Completed
56 enrolled 10 charts
PILLAR-1
Phase 2 Completed
58 enrolled 11 charts
Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia
Phase 1 Completed
241 enrolled 31 charts
A Phase I Dose Escalation Study of RAD001 Administered in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Phase 1 Completed
13 enrolled
EVINEC
Phase 2 Completed
40 enrolled
Everolimus and Lenalidomide in Treating Patients With Relapsed or Refractory Non-Hodgkin or Hodgkin Lymphoma
Phase 1/2 Completed
58 enrolled 12 charts
Panobinostat and Everolimus in Treating Patients With Recurrent Multiple Myeloma, Non-Hodgkin Lymphoma, or Hodgkin Lymphoma
Phase 1/2 Completed
124 enrolled 10 charts
HD-R3i
Phase 1/2 Completed
73 enrolled
Everolimus in Treating Patients With Lymphoma That Has Relapsed or Not Responded to Previous Treatment
Phase 2 Completed
277 enrolled 11 charts
Sorafenib and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase 1/2 Completed
103 enrolled 12 charts
RAD001 Study in Treatment of Relapsed or Refractory Acute Lymphocytic Leukemia
Phase 1/2 Completed
24 enrolled 9 charts
Everolimus and Bendamustine Hydrochloride in Treating Patients With Relapsed or Refractory Hematologic Cancer
Phase 1 Completed
20 enrolled
Everolimus (RAD001) in Primary Therapy of Waldenstrom's Macroglobulinemia
Phase 2 Completed
33 enrolled 8 charts
Everolimus, Rituximab, and Combination Chemotherapy in Treating Patients With Newly Diagnosed Untreated Diffuse Large B-Cell Lymphoma
Phase 1 Completed
26 enrolled
Study of RAD001 in Patients With Relapsed/Refractory Hodgkin Lymphoma That Has Progressed After High-dose Chemotherapy and Autologous Stem Cell Transplant and/or After Gemcitabine- or Vinorelbine- or Vinblastine-based Treatment.
Phase 2 Completed
57 enrolled 10 charts
Everolimus in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma
Phase 2 Completed
35 enrolled
S0528 Lapatinib and Everolimus in Treating Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma
Phase 1 Completed
66 enrolled
RADCHOP
Phase 1/2 Completed
46 enrolled
Panobinostat (LBH589) Plus Everolimus (RAD001) in Patients With Relapsed and Refractory Lymphoma
Phase 1/2 Completed
31 enrolled 6 charts
Everolimus Plus Rituximab for Relapsed/Refractory Diffuse Large B Cell Lymphoma
Phase 2 Completed
26 enrolled 8 charts
Multicenter Phase II Study to Evaluate the Clinical Activity and the Safety Profile of Everolimus in Marginal Zone B-cell Lymphomas (MZL)
Phase 2 Completed
30 enrolled
Panobinostat and Everolimus in Treating Patients With Relapsed or Refractory Lymphoma or Multiple Myeloma
Phase 1 Completed
11 enrolled